Compare Stocks

Insmed ($INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s NCT07765706 study is officially titled “A Phase 1, Randomized, Double-blind, Placebo-controlled, 2-Part Study to Assess Safety, Tolerability

Insmed ($INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s BiRCh study tested whether brensocatib could improve symptoms in adults with chronic rhinosinusitis without nasal polyps. The

H.C. Wainwright analyst Matthew Caufield assumed coverage of Insmed (INSM) with a Buy rating and $220 price target The firm says Brinsupri is the first and only FDA-approved therapy for

Mizuho raised the firm’s price target on Insmed (INSM) to $158 from $154 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for

Insmed ($INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s Phase 3 PALM-PPF study, officially titled “A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel Group Study of

Guggenheim lowered the firm’s price target on Insmed (INSM) to $201 from $205 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Insmed (($INSM)) has held its Q3 earnings call. Read on for the main highlights of the call. Insmed delivered a strongly positive earnings call, led by BRINSUPRI’s rapid commercial success

Roth Capital raised the firm’s price target on Insmed (INSM) to $204 from $198 and keeps a Buy rating on the shares, noting that Brinsupri sales of $400.1M in Q3

Reports Q3 revenue $524.4 M, consensus $499.48M. “Q3 marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline,” said CEO Will Lewis.

The Company raised 2026 revenue guidance for BRINSUPRI to $1.35B-$1.4B from $1.25B-$1.4B. Raised 2026 revenue view for ARIKAYCE to $460M-$470M from $450M-$470M. Continues to anticipate peak revenues for BRINSUPRI to